Literature DB >> 21112759

Risk of Hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review.

Stephen Corson1, David Greenhalgh, Norah Palmateer, Amanda Weir, Sharon Hutchinson.   

Abstract

BACKGROUND: In order to develop new ways to prevent Hepatitis C virus (HCV) transmission amongst injecting drug users (IDUs), it is necessary to fully understand the dynamics of this disease. We reviewed the evidence on three key areas of HCV transmission in this population: the rate of acute HCV infection amongst IDUs who have spontaneously resolved a previous infection, the rate of chronic HCV infection amongst IDUs who have spontaneously resolved a previous infection, and the ability of IDUs to be re-infected with either the same or a different HCV genotype.
METHODS: A literature search of PUBMED (January 1950 to January 2009), EMBASE (January 1980 to January 2009) and PsycINFO (January 1967 to January 2009) for English language, primary research papers was undertaken to identify longitudinal studies examining HCV re-infection following spontaneous viral clearance amongst IDUs.
RESULTS: The systematic review identified three studies that satisfied the inclusion and exclusion criteria. Regarding the risk of acute HCV infection amongst IDUs, the findings from the three studies were conflicting and thus provided no compelling evidence in support of an increased or decreased risk of acute infection amongst IDUs who have spontaneously resolved compared to those previously uninfected. Limited evidence was found from two studies to support a reduced risk of subsequent chronic HCV infection in those who have previously spontaneously resolved an infection. Further, two studies found IDUs who spontaneously resolved an infection can be re-infected (with comparable proportions) with either the same or a different HCV genotype.
CONCLUSION: The limited, and sometimes contradictory, evidence published in the worldwide literature highlights the need for more longitudinal studies of IDUs to fully understand the dynamics of the disease in this population.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21112759     DOI: 10.1016/j.drugpo.2010.10.007

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  6 in total

1.  A time since onset of injection model for hepatitis C spread amongst injecting drug users.

Authors:  S Corson; D Greenhalgh; S J Hutchinson
Journal:  J Math Biol       Date:  2012-08-28       Impact factor: 2.259

2.  Hepatic immunopathology during occult hepacivirus re-infection.

Authors:  Cordelia Manickam; Amanda J Martinot; Rhianna A Jones; Valerie Varner; R Keith Reeves
Journal:  Virology       Date:  2017-09-13       Impact factor: 3.616

3.  Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.

Authors:  Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

4.  Treatment of hepatitis C as prevention: a modeling case study in Vietnam.

Authors:  Nicolas Durier; Chi Nguyen; Lisa J White
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

Review 5.  Hepatitis C virus in American Indian/Alaskan Native and Aboriginal peoples of North America.

Authors:  Julia D Rempel; Julia Uhanova
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

6.  High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study.

Authors:  Rachel Sacks-Davis; Campbell K Aitken; Peter Higgs; Tim Spelman; Alisa E Pedrana; Scott Bowden; Mandvi Bharadwaj; Usha K Nivarthi; Vijayaprakash Suppiah; Jacob George; Jason Grebely; Heidi E Drummer; Margaret Hellard
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.